Myelofibrosis, a rare chronic myeloproliferative neoplasm disorder, is often an overlooked disease due to its rarity and underappreciation of the severity of clinical manifestations and burden of disease. This has led to multiple gaps in knowledge and understanding of the management of patients with myelofibrosis, especially the more severe or higher-risk forms. Drs. Aaron Gerds and Michael Grunwald discuss the current challenges that exist across the myelofibrosis landscape, including burden of disease, molecular abnormalities, pharmacologic options, and emerging novel therapies. Case studies are discussed to facilitate integration of key concepts into clinical practice.

Presenting Faculty

• 

  Aaron T. Gerds, MD, MS

  Associate Professor of Medicine
  Hematology & Medical Oncology
  Deputy Director for Clinical Research
  Cleveland Clinic Taussig Cancer Institute
  Medical Director
  Case Comprehensive Cancer Center Clinical Research Office
  Principal Investigator
  Case Lead Academic Participating Site
  Cleveland, Ohio

• 

  Michael R. Grunwald, MD

  Chief, Leukemia Division
  Director, Transplantation and Cellular Therapy Program
  Department of Hematologic Oncology and Blood Disorders
  Levine Cancer Institute
  Charlotte, North Carolina